低分子肝素钙改善胎盘循环治疗妊娠中晚期羊水过少的临床研究

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (31 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the clinical effect of Low Molecular Weight Heparin Calcium on the treatment of oligohydramnios in pregnancy. Methods A total of 80 patients with oligohydramnios in the middle and late stages of pregnancy who were treated in our hospital from January 2018 to September 2019 were selected and divided by single and double drawing. The singular was the control group (n=40), the even number was the observation group (n=40). The control group was treated with intravenous fluid replacement, the observation group was treated with low-dose Low-Molecular Weight Heparin Calcium on the basis of the control group, amniotic fluid index, S/D value of umbilical artery blood flow, delivery mode and pregnancy outcome, delivery outcome before and after treatment were compared between the two groups. Results The amniotic fluid index in the observation group was higher than that in the control group, the S/D value of umbilical artery blood flow in the observation group was lower than that in the control group,the preterm birth rate, cesarean section rate and Apgar score ≤7 in the observation group were lower than those in the control group, the differences were statistically significant (P＜0.05). The neonatal weight in the observation group was higher than that in the control group, the difference was statistically significant (P＜0.05). Conclusion Low Molecular Weight Heparin Calcium can effectively improve the S/D value of umbilical artery blood flow AFI, improve the outcome of maternal and infant.

Key words： Low Molecular Weight Heparin Calcium Circulatory treatment Middle and late pregnancy Oligohydramnios Amniotic fluid index Pregnancy outcome

Received: 18 May 2020

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

https://www.dangdaiyiyao.com/EN/ OR https://www.dangdaiyiyao.com/EN/Y2020/V27/I29/98

[1]	李嫣.小剂量低分子肝素治疗妊娠中晚期羊水过少的临床疗效[J].中国医药指南，2017，15（20）：73.
[2]	向瑾.低分子肝素治疗妊娠中晚期羊水过少的临床疗效观察[J].临床合理用药，2019，12（8）：30-31.
[3]	滕花蓉.小剂量低分子肝素治疗妊娠中晚期羊水过少的临床疗效观察[J].实用妇科内分泌电子杂志，2018，5（6）：27-28．
[4]	乐杰.妇产科学[M].7 版.北京：人民卫生出版社，2001.
[6]	霍丽红，张粉叶，周燕肖.小剂量低分子肝素治疗妊娠中晚期羊水过少的临床疗效[J].实用妇科内分泌电子杂志，2019，6（29）：38.
[5]	Di Renzo GC，Luis Bartha J，Bilardo CM.More research is needed prior to the implementation of genome-wide cellfree DNA testing in specific populations （response to letter L19 -020A：confined placental trisomy detection through cell-free DNA in the maternal circulation：benefit for pregnancy management）[J].AM J Obstet Gynecol，2019，221（3）：287.
[7]	王秀峰.小剂量低分子肝素治疗妊娠中晚期羊水过少的临床疗效[J].中国保健营养，2017，27（17）：71．
[8]	Amitai A，Wainstock T，Sheiner E，et al.The association between pregnancies complicated with isolated polyhydramnios or oligohydramnios and offspring long-term gastrointestinal morbidity[J].Arch Gynecol Obstet，2019，300（6）：1607-1612.
[9]	唐丽娟，吕小玲.补液支持治疗对孕中期羊水过少孕妇妊娠结局的影响[J].中国妇幼保健，2018，33（10）：2230-2233.
[10]	Cho H.Does fetal pulmonary venous flow impedance increase in pregnancies with placental insufficiency-related oligohydramnios in the third trimester? [J].J Ultrasound Med，2020，39（5）：859-865.
[11]	杨然，冯磊.肝素治疗羊水过少的临床疗效及其相关机制研究[J].中国现代医学杂志，2014，24（22）：43-46．
[12]	Zhang Z，Li Z，Li J，et al.Effects of natural hirudin and Low Molecular Weight Heparin in preventing deep venous thrombosis in aged patients with intertrochanteric fracture[J].Sci Rep，2018，8（1）：13-21.
[13]	杜淑丽.低分子肝素治疗妊娠晚期羊水过少的临床疗效及对患者凝血功能的影响[J].中国基层医药，2017，6（S1）：16-17.
[14]	Surbone A，Fuso L，Passera R，et al.Daily administration of low molecular weight heparin increases hepatocyte growth factor serum levels in gynaecological patients：pharmacokinetic parameters and clinical implications[J].BMC Res Notes，2017，5（1）166-168.
[15]	陈燕红，张金艳.治疗量低分子肝素钙治疗羊水过少的临床疗效及其安全性[J].临床合理用药杂志，2019，12（36）：85-86.